Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Consolidated Net Income (2022 - 2025)

Historic Consolidated Net Income for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$4.3 million.

  • Atara Biotherapeutics' Consolidated Net Income rose 8035.97% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.4 million, marking a year-over-year increase of 11754.08%. This contributed to the annual value of -$85.4 million for FY2024, which is 6909.89% up from last year.
  • Per Atara Biotherapeutics' latest filing, its Consolidated Net Income stood at -$4.3 million for Q3 2025, which was up 8035.97% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Consolidated Net Income ranged from a high of $38.0 million in Q1 2025 and a low of -$88.1 million during Q1 2022
  • Its 4-year average for Consolidated Net Income is -$36.9 million, with a median of -$31.8 million in 2024.
  • As far as peak fluctuations go, Atara Biotherapeutics' Consolidated Net Income plummeted by 48507.53% in 2023, and later skyrocketed by 21970.9% in 2025.
  • Atara Biotherapeutics' Consolidated Net Income (Quarter) stood at -$74.7 million in 2022, then grew by 18.72% to -$60.7 million in 2023, then skyrocketed by 79.09% to -$12.7 million in 2024, then skyrocketed by 66.1% to -$4.3 million in 2025.
  • Its last three reported values are -$4.3 million in Q3 2025, $2.4 million for Q2 2025, and $38.0 million during Q1 2025.